Clinical Trials And Drug EfficacyManagement has reported higher compliance than in the previous trial and patients have good disease control, indicating a chance for positive outcomes in the '204 trial.
Drug Market PotentialThe CAH opportunity has a large enough rare disease market with approximately 20,000-30,000 patients in the U.S. and around 250 new patients identified via newborn screening annually.
Financial PerformanceSpruce Biosciences ended 2Q24 with $69.7M in cash and cash equivalents, which is expected to be sufficient to fund operations at least through the end of 2025 based on the company's current strategic plan.